This site is intended for US healthcare professionals

CKD progression in T2D destroys kidneys

CKD PROGRESSION IN T2D:

AN EVOLVING UNDERSTANDING OF THE DAMAGE BEING DONE

Luiza Caramori, MD, PhD, MSc, discusses the prevalence of CKD and T2D, as well as the driving factors behind CKD progression
CKD Progression in T2D video poster with play button

3 MAJOR DRIVERS OF CKD PROGRESSION IN PATIENTS WITH T2D1-4

Metabolic drivers of CKD icon

Metabolic Drivers

  • Elevated HbA1c
  •  
Hemodynamic drivers of CKD icon

Hemodynamic Drivers

  • Elevated BP
  • High intraglomerular pressure
Inflammatory and fibrotic drivers of CKD icon

Inflammatory
and Fibrotic Drivers

  • Presence and/or release of proinflammatory proteins and profibrotic proteins
  •  

CKD Progression

Current guideline-recommended therapies mainly focus on metabolic and hemodynamic drivers in patients with chronic kidney disease and type 2 diabetes, leaving inflammation and fibrosis largely unaddressed.5-7

Patients remain at risk of CKD progression even when their HbA1c and BP are controlled.1,2,8,9

Thank you for visiting our site. The questions you'll see throughout are completely voluntary. If you choose to answer the questions, you'll gain access to our video library and other resources.

Inflammatory and fibrotic drivers of CKD icon

Current standard of care leaves patients vulnerable to a largely unaddressed driver of CKD progression: inflammation and fibrosis1-3,7

Next page

BP: blood pressure; CKD: chronic kidney disease; HbA1c: glycated hemoglobin; KDIGO: Kidney Disease Improving Global Outcomes; T2D: type 2 diabetes.

References:

  • Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10.1155/2015/697010.
  • Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
  • Black LM, et al. J Histochem Cytochem. 2019;67(9):663–681.
  • Tesch GH, et al. Front Pharmacol. 2017;8. doi:10.3389/fphar.2017.00313.
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1–150.
  • Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1–S115.
  • American Diabetes Association. Diabetes Care. 2021;44(suppl 1):S1–S232.
  • Duckworth W, et al; VADT Investigators. N Engl J Med. 2009;360(2):129–139.
  • The ACCORD Study Group. N Engl J Med. 2010;362(17):1575–1585.